Kidney disease and nephrology
Research activity centers on membranous nephropathy, primary membranous nephropathy, and idiopathic nephrotic syndrome, with additional work in end-stage kidney disease on chronic dialysis therapy and chronic kidney disease complicated by hyperkalemia.
- Nephrotic syndrome
- Anti-CD20-resistant kidney disease
- Potassium management in CKD and dialysis
These studies include treatment strategies for proteinuria, relapse prevention, and electrolyte control in advanced renal disease.
Oncology and solid tumours
The sponsor is involved in clinical research on advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, as well as stage III non-small cell lung cancer with locoregional relapse.
- Homologous recombination deficiency-positive ovarian cancer
- Bevacizumab-based maintenance treatment
- Relapsed non-small cell lung cancer
Its oncology portfolio also includes biomarker-linked treatment approaches and post-treatment disease control in recurrent malignancies.
Neurology and neuroprotection
Clinical trials address amyotrophic lateral sclerosis and neurological injury after out-of-hospital cardiac arrest, with interest in preserving functional status and limiting brain injury after resuscitation.
- Amyotrophic lateral sclerosis
- Post-cardiac arrest neurological injury
- Functional disability progression
This area reflects a focus on neurodegenerative disease and acute neurological recovery in critical care settings.
Critical care and emergency medicine
Research extends to tracheal intubation, vasopressor use, and management of cardiovascular collapse in critically ill adults, alongside experimental approaches in post-resuscitation ventilation.
- Endotracheal intubation
- Hemodynamic instability
- Post-resuscitation care
These studies address acute intervention strategies in unstable hospitalized patients and emergency procedures.
Translational and immunologic therapy
The sponsor’s portfolio includes antibody-based and biomarker-informed research in autoimmune kidney disease and cancer immunotherapy, with attention to CD38, CD20, durvalumab, and ceralasertib.
- Antibody therapy in renal disease
- Immune-targeted oncology
- Biomarker-driven treatment selection
Its research spans immune modulation in kidney disorders and targeted treatment combinations in solid tumours.
